Our Science

Our Method

At EpiDisease, we take pride in our commitment to compliance with international standards, fostering continuous improvement through iterative processes, and maintaining rigorous internal controls. Continuous improvement is at the heart of everything we do. We understand that progress is an ongoing journey, and we embrace it with enthusiasm. Through iterative processes, we learn from every step, making each one better than the last. This relentless pursuit of improvement drives us to innovate, adapt, and evolve to meet the dynamic needs of our clients through the Design Thinking methodology.

Our Quality Policy

EpiDisease, in its pursuit of transforming science into biomedical solutions that improve people’s health and well-being, aims to develop and commercialize products for the diagnosis and prognosis of human diseases based on epigenetic biomarkers. It also offers diagnostic and research support services in the fields of epigenetics and R&D. To this end, the company is committed to quality in every aspect of its business—from product and/or service quality to post-sale support. At EpiDisease, we understand that service quality is a customer right. Therefore, we have implemented a Management Model and a Quality Policy, which is defined by the following principles:
We are committed to complying with the customer, legal, and regulatory requirements applicable to the activities carried out by EpiDisease. To this end, we have implemented a Management System aligned with international standards, whose transparency and compliance are continuously verified by external and independent bodies. Likewise, we are committed to providing products and services that meet their intended use and fulfill user needs.
We consider the standardization of our activities and their continuous improvement to be essential elements for consistently enhancing the quality of our results. Therefore, within our quality management system, special importance is given to the identification and resolution of errors, as well as the awareness of their prevention.
The organization is not only committed to maintaining high quality standards in the manufacturing of its products, but also in the development of epigenetic applications aimed at achieving a significant impact on improving people’s health and well-being, as well as in third-party research support services.
We are committed to maintaining high standards of safety and reliability in our products and services, as they support decisions of great importance for individuals. Therefore, we are committed to carrying out our activities under good professional practice, which includes the impartiality of our actions, ensuring that commercial, financial, or other pressures do not compromise that impartiality.
EpiDisease Management sets the guidelines and provides the necessary support and resources for the development of activities, demonstrating its commitment to quality. Consequently, all personnel assume responsibility for the tasks they perform, always ensuring compliance with applicable regulations and standards, with the ultimate goal of meeting established requirements and fostering continuous improvement.
What is the focus of our science?

Epigenetics

What is epigenetics?

Epigenetics is the study of modifications in gene expression without alterations in the DNA sequence.

DNA Methylation

This process is one of the most studied epigenetic mechanisms and is essential for the proper development of organisms.

DNA Compaction

At EpiDisease, we are experts in analyzing histone post-translational modifications using mass spectrometry and immunological techniques.

miRNAs or Non-Coding RNAs

It has been estimated that the total number of miRNAs in the human genome may be around 2,000.

1. DNA Methylation

DNA methylation consists of the addition of a methyl group at the 5′ position of cytosine in the DNA.
Alterations in DNA methylation are associated with genomic instability and proper control of gene expression, and they lead to the development of various diseases (e.g., cancer, neurological disorders, metabolic syndrome, etc.). Methylation mainly occurs at CpG sites. DNA methylation is catalyzed by DNA methyltransferases (DNMTs), which transfer the methyl group from the S-adenosylmethionine molecule. At EpiDisease, we are experts in analyzing DNA methylation and identifying DNA methylation-based signatures associated with various human diseases.

2. DNA Compaction

Histones are a family of proteins involved in the compaction of DNA into structural units known as nucleosomes.
Each nucleosome is composed of DNA wrapped around a histone octamer. Each histone octamer consists of 2 units of each histone: H2A, H2B, H3, and H4. The chain of nucleosomes then coils upon itself, forming a 30 nm spiral known as a solenoid, where histone H1 binds to the linker DNA region between different nucleosomes to maintain the chromatin structure.
Histones can be chemically modified, with the main post-translational modifications (PTMs) being acetylation, methylation, and phosphorylation, although many others also exist. These PTMs make up the “histone code,” which can alter gene expression patterns by modifying chromatin structure—either activating or silencing specific genes. It is hypothesized that alterations in histone PTM patterns deregulate chromatin compaction, ultimately leading to oncogenic transformation and cancer development. This hypothesis is supported by the discovery of aberrant histone PTM patterns in a large number of tumors. At EpiDisease, we are experts in analyzing histone post-translational modifications in various types of biological samples using mass spectrometry and immunological techniques.

3. miRNAs or Non-Coding RNAs

The discovery of microRNAs (miRNAs) has revolutionized medical science due to their potential applications.
miRNAs are small non-coding RNAs of 19–23 nucleotides that can repress gene expression. It is estimated that up to 30% of mammalian genes are regulated by miRNAs. For this reason, specific expression profiles are being identified in various diseases. In recent years, the involvement of miRNAs has been demonstrated in the development of many types of cancer, neurodegenerative diseases, metabolic disorders, aging, and frailty. The high stability of miRNAs in serum, plasma, urine, saliva, and other fluids makes these molecules suitable for use as biomarkers in a clinical laboratory.

Discover our latest projects

We present to you our latest lines of research and action.